Daiichi Sankyo and MorphoSys Collaborate on Antibody Therapeutics Against Nosocomial Infections
Partnership will exploit MorphoSys’ newest antibody library, HuCAL Platinum.
Daiichi Sankyo and MorphoSys formed an alliance to discover and develop new antibody therapeutics against hospital-acquired infections. MorphoSys says the deal is the first to use its HuCAL Platinum®-based antibody technology in the field of infectious disease drug discovery.
The companies will work together to apply HuCAL Platinum (MorphoSys latest version of its antibody libraries) along with established and novel approaches to generate optimized, fully human therapeutic antibodies against targets associated with nosocomial infections. Daiichi Sankyo has also committed funding to develop infectious disease-specific technology at MorphoSys, which the companies say will be used to identify the most effective antibody-based drugs.
Under terms of the agreement MorphoSys will receive committed license fees and R&D funding in addition to success-based development milestones and potential royalties on sales of marketed drugs.
MorphoSys and Daiichi Sankyo have been collaborating since 2006 on therapeutic antibody discovery and development and have four active therapeutic antibody programs on the go, primarily in the field of oncology field.